MONTREAL, Oct. 2 /CNW Telbec/ - Arura Pharma Inc. (TSX-V: ARP) ("Arura")
is pleased to announce that one of its products, a Hand Soap, Olive Oil and
Coriander manufactured by its wholly owned subsidiary Laboratoire
Cosmepro Inc. and sold under the Uniprix Private Label name, has received the
2007 "Home and Health Award" in the "Bath and Body-Hand Soap" category,
presented annually, from the Private Label Manufacturers Association. The
Private Label Manufacturers Association is an association with offices in
Amsterdam, New York and Hong Kong, devoted exclusively to the private label
industry, whose product sales under various labels exceed $43 billion annually
in the United States and regrouping corporation from more than 70 countries.
"We are honoured and delighted to have our manufacturing expertise,
innovation, and product development expertise recognized internationally by
such a prestigious award," said Pierre Fortin, Arura's Chief Operations
Officer. "This award underlines our continued commitment to develop the
highest quality products and our unswerving dedication to excellence and will
be used to leverage our market United States and international markets
penetration", added Mr. Fortin.
Options granting and shares issuance
Arura also granted 416,666 options to its new director Réjean Duguay.
These options are vesting over a 10 months period and each option permits to
Mr. Duguay to purchase one common share of Arura at a price of $0.125 per
share for a period of five (5) years from the date of grant. The options and
any securities issued upon the exercise of the options are subject to a
four-month hold period. The options were granted pursuant to Arura's incentive
stock option plan. The option grant is subject to regulatory approval and
approval of the shareholders of Arura fixing the number of shares subject to
Arura also obtained from the TSX Venture Exchange the authorisation to
issue 106,250 common shares to Luc Dubé and 143,750 common shares to Yvon
Fortier at a deemed price of $0.15 per common share to settle outstanding
debts for $15,937.50 and $21,562.50 respectively. The common shares to be
issued are subject to a hold period of four months.
About Arura Pharma Inc.
Arura is a specialty pharmaceutical company consisting of two business
units, namely an established consumer health business unit manufacturing and
distributing beauty and personal hygiene products in Canada and in the United
States and an emerging specialty pharmaceutical business unit geared at
acquiring and commercializing established prescription drugs and medical
devices in the oncology, wound care and neurology sectors, amongst others.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this press release.
For further information:
For further information: please visit the web site www.Cosmepro.com or
contact: Daniel Pharand, Chairman, Arura Pharma Inc., (514) 984-4431,
firstname.lastname@example.org; Ali Moghaddam, Chief Executive Officer, Arura Pharma
Inc., (450) 442-2545 ext. 233, email@example.com; Pierre Fortin,
Chief Operating Officer, Arura Pharma Inc., (450) 442-2545 ext. 230,